About
Latus develops gene therapies utilizing engineered adeno-associated virus (AAV) capsids to enable targeted and cell-specific delivery of treatments for central nervous system and peripheral diseases, aiming to improve efficacy and safety at lower doses.
Explore Latus's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.